Exagen Statistics
Total Valuation
Exagen has a market cap or net worth of $71.34 million. The enterprise value is $72.43 million.
Important Dates
The next estimated earnings date is Monday, March 17, 2025, before market open.
| Earnings Date | Mar 17, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Exagen has 17.64 million shares outstanding. The number of shares has increased by 3.06% in one year.
| Current Share Class | 17.64M |
| Shares Outstanding | 17.64M |
| Shares Change (YoY) | +3.06% |
| Shares Change (QoQ) | +0.42% |
| Owned by Insiders (%) | 11.61% |
| Owned by Institutions (%) | 32.39% |
| Float | 8.47M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.30 |
| Forward PS | 1.15 |
| PB Ratio | 5.46 |
| P/TBV Ratio | 5.50 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.30 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.05, with a Debt / Equity ratio of 1.84.
| Current Ratio | 4.05 |
| Quick Ratio | 3.58 |
| Debt / Equity | 1.84 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -6.88 |
Financial Efficiency
Return on equity (ROE) is -83.86% and return on invested capital (ROIC) is -21.54%.
| Return on Equity (ROE) | -83.86% |
| Return on Assets (ROA) | -18.42% |
| Return on Capital (ROIC) | -21.54% |
| Revenue Per Employee | $311,458 |
| Profits Per Employee | -$94,564 |
| Employee Count | 179 |
| Asset Turnover | 1.07 |
| Inventory Turnover | 8.88 |
Taxes
In the past 12 months, Exagen has paid $33,000 in taxes.
| Income Tax | 33,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +102.53% in the last 52 weeks. The beta is 1.42, so Exagen's price volatility has been higher than the market average.
| Beta (5Y) | 1.42 |
| 52-Week Price Change | +102.53% |
| 50-Day Moving Average | 4.00 |
| 200-Day Moving Average | 2.69 |
| Relative Strength Index (RSI) | 52.22 |
| Average Volume (20 Days) | 201,198 |
Short Selling Information
The latest short interest is 79,225, so 0.45% of the outstanding shares have been sold short.
| Short Interest | 79,225 |
| Short Previous Month | 78,064 |
| Short % of Shares Out | 0.45% |
| Short % of Float | 0.94% |
| Short Ratio (days to cover) | 3.12 |
Income Statement
In the last 12 months, Exagen had revenue of $55.75 million and -$16.93 million in losses. Loss per share was -$0.94.
| Revenue | 55.75M |
| Gross Profit | 32.78M |
| Operating Income | -15.40M |
| Pretax Income | -17.28M |
| Net Income | -16.93M |
| EBITDA | -13.58M |
| EBIT | -15.40M |
| Loss Per Share | -$0.94 |
Full Income StatementBalance Sheet
The company has $22.04 million in cash and $23.74 million in debt, giving a net cash position of -$1.70 million or -$0.10 per share.
| Cash & Cash Equivalents | 22.04M |
| Total Debt | 23.74M |
| Net Cash | -1.70M |
| Net Cash Per Share | -$0.10 |
| Equity (Book Value) | 12.87M |
| Book Value Per Share | 0.73 |
| Working Capital | 26.78M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$5.29 million and capital expenditures -$475,000, giving a free cash flow of -$5.77 million.
| Operating Cash Flow | -5.29M |
| Capital Expenditures | -475,000 |
| Free Cash Flow | -5.77M |
| FCF Per Share | -$0.33 |
Full Cash Flow StatementMargins
Gross margin is 58.80%, with operating and profit margins of -27.62% and -30.36%.
| Gross Margin | 58.80% |
| Operating Margin | -27.62% |
| Pretax Margin | -30.30% |
| Profit Margin | -30.36% |
| EBITDA Margin | -24.37% |
| EBIT Margin | -27.62% |
| FCF Margin | n/a |
Dividends & Yields
Exagen does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.06% |
| Shareholder Yield | -3.06% |
| Earnings Yield | -23.93% |
| FCF Yield | -8.16% |
Analyst Forecast
The average price target for Exagen is $7.50, which is 85.41% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $7.50 |
| Price Target Difference | 85.41% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 13.10% |
| EPS Growth Forecast (5Y) | -37.38% |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Exagen has an Altman Z-Score of -7.81 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -7.81 |
| Piotroski F-Score | 3 |